Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study
Abstract Purpose This study was performed to investigate the efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer (NSCLC) in the real world. Methods Data on clinicopathological features, efficacy and adverse events (AEs) were collected retr...
Main Authors: | Ke Ma, Qianqian Guo, Xingya Li |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-05-01
|
Series: | BMC Pulmonary Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12890-023-02470-z |
Similar Items
-
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
by: Lan-Lan Pang, et al.
Published: (2023-01-01) -
Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer
by: Claudio Martin, et al.
Published: (2022-12-01) -
The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study
by: Yu Feng, et al.
Published: (2022-09-01) -
Application basis of combining antiangiogenic therapy with radiotherapy and immunotherapy in cancer treatment
by: Meng Yuan, et al.
Published: (2022-11-01) -
Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date
by: Raybould AL, et al.
Published: (2020-09-01)